Lisa has been taking GDC-0032 since last Friday (12/14/2012) and is feeling pretty good. GDC-0032 is a new drug in the fight against cancer. It works by blocking the PIK3 protein, which helps cancer cells grow. She is receiving this drug as part of a Phase I clinical trial at MGH.
Unlike T-DM1, her previous treatment, which was given as an infusion every three weeks, GDC-0032 is taken in pill form once every day. Having the treatment in pill form, which can be taken at home, is a true convenience over an infusion, which must be done at the hospital. Ironically, we will be making more trips to Boston than we were while Lisa was in the T-DM1 trial since the Phase I GDC-0032 trial requires a weekly visit to MGH for exams and blood tests. At least she’ll get a break from the infusion unit.
Thank you everyone for your thoughts and prayers.
Have wonderful holiday season and a Merry Christmas.